RxDoctor Payments DataLook up a doctor →

Melanie Ketchandji, MD

Urology · Tulsa, OKNPI 1811247885

Payments from drug & device makers

$111,012in general payments, 2019–2025

Across 497 payments — averaging $223.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$54K
  • Medtronic$49K
  • Axonics, Inc.$3K
  • Procept Biorobotics Corporation$1K
  • Boston Scientific$945
  • Sumitomo Pharma America, Inc.$902
  • plus $3K from 25 others

What the payments were for

  • Consulting fees$36,35633%
  • Speaking & faculty fees$39,29235%
  • Travel & lodging$17,80316%
  • Food & beverage$10,1109%
  • Education$7,4527%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$111,012 in reported general payments places this provider in the 95th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$255,674
Medicare patients
669
Services billed
3,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron508$341,298
MyrbetriqMirabegron105$58,968
Estradiol209$13,177
Solifenacin Succinate53$3,907
Tamsulosin Hcl355$3,809
Methenamine Hippurate41$3,403
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst202$3,069
Finasteride211$2,092
Tolterodine Tartrate ErTolterodine Tartrate37$1,860
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen149$1,012
NitrofurantoinNitrofurantoin Macrocrystal39$934
Fosfomycin Tromethamine13$882
Fesoterodine Fumarate ErFesoterodine Fumarate14$807
Oxybutynin Chloride ErOxybutynin Chloride73$708
Cephalexin64$346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$902$341,298508 claims
Astellas Pharma US IncMyrbetriq$346$58,968105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 145 urology providers in Oklahoma.

Other urology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →